Article
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Published 02 Oct 2024
Article
Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance
Published 09 Sep 2024
Article
Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected
Published 09 Sep 2024
Article
Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024
Published 06 Sep 2024
Article
Recce Pharmaceuticals – Executive Interview
Published 07 Aug 2024
Article
Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million
Published 05 Aug 2024
Article
Recce scores US$2M deal from US Department of Defense for burn wound infections gel
Published 16 Jul 2024
Article
Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel
Published 15 Jul 2024
Article
Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327
Published 28 Jun 2024
Article
Recce Starts Phase 2 R327 Gel trial for bacterial skin infections
Published 25 Jun 2024
Article
Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327
Published 18 Jun 2024
Article
Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound
Published 12 Jun 2024
Article
Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound
Published 11 Jun 2024
Article
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
Published 27 May 2024
Article
Recce Pharma heading closer to full efficacy data for flagship R327
Published 15 May 2024
Article
Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327
Published 09 May 2024
Article
Recce Pharma picks up Chinese patent for anti-infective drugs
Published 07 May 2024
Article
Recce weighs in on Q1 2024 as cash increases 100%
Published 22 Apr 2024
Article
Recce Pharmaceuticals up 6% on new antibiotic production milestone
Published 16 Apr 2024
Article
Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024
Published 11 Apr 2024
Article
Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel
Published 09 Apr 2024
Article
Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel
Published 08 Apr 2024
Article
Recce Pharmaceuticals inks new patent for flagship drug in Israel
Published 03 Apr 2024
Article
Recce reaches testing milestone for UTI, Uroseptis antibiotic
Published 22 Mar 2024
Article
Recce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsis
Published 18 Mar 2024
Article
Recce reaches testing milestone for UTI, Urosepsis antibiotic
Published 17 Mar 2024
Article
Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial
Published 13 Mar 2024
Article
Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital
Published 13 Mar 2024
Article
Biotech around the World: The Low-Down on the Land Down Under
Published 03 Mar 2024
Article
BioBoss Podcast - CEO James Graham
Published 29 Feb 2024
Article
Recce Pharmaceuticals leads the way in collaborative Anti-Infective research
Published 27 Feb 2024
Article
Recce Pharmaceuticals wins safety approval to expand wound infection trial
Published 26 Feb 2024
Article
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
Published 15 Feb 2024
Article
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
Published 08 Feb 2024
Article
Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push
Published 06 Feb 2024
Article
Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong
Published 28 Jan 2024
